HC Wainwright Brokers Reduce Earnings Estimates for LEXX

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Lexaria Bioscience in a note issued to investors on Monday, December 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.12) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.46) EPS.

Lexaria Bioscience Price Performance

LEXX opened at $2.70 on Wednesday. The stock has a market cap of $47.12 million, a P/E ratio of -5.74 and a beta of 0.99. The stock’s 50 day simple moving average is $2.58 and its 200 day simple moving average is $2.97. Lexaria Bioscience has a 1-year low of $1.20 and a 1-year high of $6.85.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Armistice Capital LLC purchased a new position in Lexaria Bioscience in the second quarter valued at about $2,836,000. Geode Capital Management LLC raised its position in Lexaria Bioscience by 31.0% in the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after purchasing an additional 35,608 shares during the period. Renaissance Technologies LLC purchased a new position in Lexaria Bioscience in the second quarter valued at about $63,000. HighTower Advisors LLC purchased a new position in Lexaria Bioscience in the third quarter valued at about $40,000. Finally, XTX Topco Ltd raised its position in Lexaria Bioscience by 47.8% in the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after purchasing an additional 6,024 shares during the period. 13.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lexaria Bioscience

In other news, CEO Richard Christopher bought 22,828 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average cost of $2.24 per share, with a total value of $51,134.72. Following the transaction, the chief executive officer now owns 22,828 shares of the company’s stock, valued at $51,134.72. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 26.40% of the stock is owned by insiders.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.